Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting.
Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting. Clin Adv Hematol Oncol. 2019 Jan;17 Suppl 2(1):1-20 Authors: PMID: 31545309 [PubMed - in process]
Leukemia, Published online: 15 November 2019; doi:10.1038/s41375-019-0638-yDistinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
AbstractThe immunohistochemical stain ERG is a useful diagnostic marker for leukemia cutis. Translocations involving theERG gene have been identified in acute myeloid leukemia (AML) and it plays critical roles in differentiation of hematopoietic stem cells. However, little is known about ERG expression in the bone marrow or in myeloid neoplasms. The aim of this study is to characterize ERG expression in normal bone marrow specimens, and those with various myeloid neoplasms. We performed immunohistochemical studies assessing ERG expression in bone marrow biopsies obtained over a 1-year period, in which myeloperoxidase (MPO)...
Leukemia, Published online: 14 November 2019; doi:10.1038/s41375-019-0629-zHypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms
AbstractHematologic malignancies include several lymphoproliferative and myeloproliferative disorders, many of which are frequently encountered in current health care settings. These malignancies frequently affect the gastrointestinal (GI) tract, either by secondary extranodal or extramedullary extension to the GI tract, or as a primary process arising in the GI tract. In fact, the GI tract may represent the most common extranodal site of involvement in many of them, such as lymphoma. Furthermore, in the current era of improved cancer treatment and advanced transplant procedures with increased survival, it has been quite c...
Journal of Medicinal ChemistryDOI: 10.1021/acs.jmedchem.9b01348
Leukemia, Published online: 07 November 2019; doi:10.1038/s41375-019-0616-4Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin
The objective of this article is to provide an overview of published evidence addressing the key question of the mechanisms underlying ruxolitinib-induced immunosuppression.
Condition: Myelofibrosis Intervention: Sponsor: Fondazione per la Ricerca Ospedale Maggiore Recruiting
Background: Myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are characterized by excessive production of blood cells. Treatment of MPNs patients has an important effect thereby reducing morbidity and mortality.Objective: To evaluate the effect of cytoreductive treatment on some hematological and biochemical parameters in MPNs patients treated at a hemato-oncology Centre in Erbil, Iraq.Methods: A total of 185 patients diagnosed with PV, ET, and PMF (111 males and 74 females with a mean age of 50.8 ±3.2 years, range: 46-73) were assign...